Vaxcyte, Inc.
PCVX
Kedudukan dalam Saham
#2069
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Harga Saham
$65.22
Modal Pasaran
$10.00B
Perubahan (1 hari)
2.51%
Perubahan (1 tahun)
53.86%
Negara
US
Perdagangan Vaxcyte, Inc. (PCVX)
Kategori
Healthcare
Pendapatan untuk Vaxcyte, Inc. (PCVX)
Pendapatan pada Jun 2026 TTM: $-1.06B
Menurut laporan kewangan terkini Vaxcyte, Inc., pendapatan semasa syarikat ialah $-1.06B. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-402.27M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-223.49M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Vaxcyte, Inc. dari 2017 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-1.06B | 129.40% |
| 2024 | $-463.93M | 15.33% |
| 2023 | $-402.27M | 80.00% |
| 2022 | $-223.49M | 123.31% |
| 2021 | $-100.08M | 12.17% |
| 2020 | $-89.22M | 77.46% |
| 2019 | $-50.27M | 70.51% |
| 2018 | $-29.49M | 71.05% |
| 2017 | $-17.24M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -595.64% |
US
|
|
| $-3.09B | 190.06% |
US
|
|
| $-4.02B | 277.37% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -283.29% |
NL
|
